Xavant and Promedia Medizintechnik at Norddeutsche Anästhesie-Tage in Hamburg, Germany (13 – 14 December 2019)

Hamburg, Germany, 13 – 14 December 2019 – Xavant Technology (Pty) Ltd and Promedia Medizintechnik will be exhibiting at the Norddeutsche Anästhesie-Tage at Hotel Grand Elysée Hamburg, Germany, from 13 – 14 December 2019. Visit the Promedia Medizintechnik booth for a demonstration of the Stimpod NMS450X TOF Monitor’s new features. You can learn more about…

Xavant and Promedia Medizintechnik at Bayerische Anästhesietage in Garmisch-Partenkirchen, Germany (18-19 October 2019)

Garmisch-Partenkirchen, Germany, 18 – 19 October 2019 – Xavant Technology (Pty) Ltd and Promedia Medizintechnik will be exhibiting at the 49th Bayerische Anästhesietage in Garmisch-Partenkirche, Germany, from 18 – 19 October 2019. Visit the Promedia Medizintechnik booth for a demonstration of the Stimpod NMS450X TOF Monitor’s new features. You can learn more about the Stimpod…

Xavant and Promedia Medizintechnik at Münsteraner Anästhesie-Symposium in Münster, Germany (28 – 30 Nov 2019)

Münster, Germany, 28 – 30 November 2019 – Xavant Technology (Pty) Ltd and Promedia Medizintechnik will be exhibiting at the 51st Münsteraner Anästhesie-Symposium in Münster, Germany from 28 – 30 November 2019. Visit the Promedia Medizintechnik booth for a demonstration of the Stimpod NMS450X TOF Monitor’s new features. You can learn more about the Stimpod…

Xavant and Promedia Medizintechnik at the 21st Capital Congress of the DGAI in Berlin (19 – 21 September 2019)

Berlin, Germany, 19 – 21 September 2019 – Xavant Technology (Pty) Ltd and Promedia Medizintechnik will be exhibiting at the 21st Capital Congress of the Deutsche Gesellschaft für Anästhesiologie & Intensivmedizin in Berlin, Germany from 19 to 21 September 2019. Visit the Promedia Medizintechnik booth for a demonstration of the Stimpod NMS450X TOF Monitor’s new…

Stimpod NMS460 Receives FDA Clearance (USA)

Pretoria, South Africa – Xavant Technology (Pty) Ltd today announced that the U.S. Food and Drug Administration (FDA) cleared their Stimpod NMS460. With the U.S. patent awarded on proprietary hybrid pulsed radio frequency (PRF) waveform, this non-invasive neuromodulation device is focused on the symptomatic relief and management of chronic intractable pain, as well as an adjunctive…